Compare Novo Nordisk A/S (NVO) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vistra Corp — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Vistra Corp trades at $162.33 (market cap $53.27B). The key difference: Novo Nordisk A/S is far larger — about 4.1× Vistra Corp's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | VST | |
|---|---|---|
Market Cap | $220.53B | $53.27B |
Sector | Health | Technology |
52-Week High | $71.70 | $217.92 |
52-Week Low | $35.29 | $134.71 |
Enterprise Value | $239.49B | $75.03B |
Dividend Yield | 3.63% | 0.58% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
